Ishita Drugs & Indus Complete Financial Statements
In FYNone, Ishita Drugs & Indus (ISHITADR) reported revenue ₹17 Cr, net profit ₹1 Cr and EPS ₹3.00, with a net profit margin of 6.7% and ROE of 9.1%. Full financial statements from FY2015 to FY2025 (11 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Review ISHITADR earnings multiple to evaluate earnings-based valuation against sector peers.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
ISHITADR Revenue, Net Profit & EBITDA — Year-on-Year Growth
ISHITADR YoY (March 2025 vs Period) — revenue +13.3%, expenses +7.1%. For live price, earnings ratios and company overview, see ISHITADR stock price BSE.
ISHITADR Income Statement — Revenue, EBITDA & Net Profit
Ishita Drugs & Indus revenue ₹17 Cr, EBITDA ₹1 Cr, net profit ₹1 Cr, EPS ₹3.00 (None) — net profit margin 6.7%. Explore ISHITADR fundamental worth to estimate fundamental worth using multiple valuation models.
| Particulars | None | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17 | 15 | 16 | 12 | 14 | 14 | 15 | 9 | 7 | 7 | 7 | 8 |
| Expenses | 15 | 14 | 14 | 11 | 13 | 13 | 14 | 9 | 6 | 6 | 7 | 7 |
| EBITDA | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 |
| Operating Profit Margin % | 6.00% | 7.00% | 6.00% | 6.00% | 8.00% | 7.00% | 5.00% | 6.00% | 7.00% | 6.00% | 4.00% | 4.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Earnings Per Share (₹) | 3.00 | 2.90 | 2.50 | 1.93 | 2.69 | 2.77 | 1.83 | 1.18 | 0.83 | 0.61 | 0.46 | 0.74 |
ISHITADR Balance Sheet — Assets, Liabilities & Shareholders' Equity
ISHITADR total assets ₹16 Cr, total equity ₹11 Cr, total liabilities ₹ Cr (2025) — ROE 9.1%.
| Particulars | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| Total Assets | 16 | 11 | 11 | 11 | 9 | 10 | 8 | 7 | 7 | 8 | 7 |
| Current Assets | 15 | 10 | 10 | 10 | 8 | 8 | 7 | 6 | 6 | 7 | 6 |
| Fixed Assets | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Capital Work in Progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 4 | 3 | 3 | 4 | 3 | 5 | 4 | 3 | 3 | 2 | 2 |
| Other Assets | 12 | 7 | 7 | 6 | 5 | 3 | 3 | 3 | 4 | 5 | 4 |
| LIABILITIES | |||||||||||
| Total Liabilities | |||||||||||
| Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-Current Liabilities | |||||||||||
| SHAREHOLDERS' EQUITY | |||||||||||
| Total Equity | 11 | 10 | 9 | 9 | 8 | 7 | 6 | 6 | 6 | 6 | 6 |
| Share Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves & Surplus | 8 | 7 | 6 | 6 | 5 | 4 | 3 | 3 | 3 | 3 | 3 |
ISHITADR Cash Flow Statement — Operating, Investing & Financing
Ishita Drugs & Indus operating cash flow ₹-4 Cr, investing ₹-1 Cr, financing ₹4 Cr, net cash flow ₹0 Cr (2025).
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | -4 | 2 | -3 | 3 | -1 | 1 | 1 | 1 | 1 | 0 | 0 |
| Investing Activities | -1 | 0 | 1 | -1 | 3 | -1 | -1 | -1 | -1 | 0 | 0 |
| Financing Activities | 4 | -1 | 1 | 0 | 0 | 0 | 0 | 0 | -1 | 1 | 0 |
| Net Cash Flow | 0 | 1 | -1 | 2 | 2 | 0 | 0 | 0 | -1 | 1 | 0 |